Cover Image
市場調查報告書

非增殖性糖尿病視網膜病變(NPDR):全球臨床實驗檢討

Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018

出版商 GlobalData 商品編碼 304747
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
非增殖性糖尿病視網膜病變(NPDR):全球臨床實驗檢討 Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018
出版日期: 2018年03月31日 內容資訊: 英文 69 Pages
簡介

本報告提供非增殖性糖尿病視網膜病變(NPDR)相關的臨床研究最新趨勢分析,提供疾病·治療方法概要,並彙整臨床實驗的主要國家,G7各國及E7(新興7國)的臨床實驗數及實驗對象採用狀況,地區、PHASE、階段別的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

目錄

簡介

  • 非增殖性糖尿病視網膜病變(NPDR)
  • 本報告概要

各地區的臨床實驗情形

各國臨床實驗數量和平均實驗人數

  • 亞太地區主要國家的臨床實驗數量
  • 歐洲主要國家的臨床實驗數量
  • 北美主要國家的臨床實驗數量
  • 中東及非洲主要國家的臨床實驗數量

G7各國的臨床實驗數量:代謝性疾病臨床實驗數量中非增殖性糖尿病視網膜病變(NPDR)的比率

G7各國的臨床實驗數量:Phase別

G7各國的臨床實驗數量:各進展狀況

E7(新興7個國家)的臨床實驗數量:代謝性疾病臨床實驗數量中非增殖性糖尿病視網膜病變(NPDR)的比率

E7(新興7個國家)的臨床實驗數量:Phase別

E7(新興7個國家)的臨床實驗數量:各進展狀況

Phase別臨床實驗數量

  • 進行中的臨床實驗:不同階段

各進展狀況臨床實驗數量

尚未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Novartis AG
    • Valeant Pharmaceuticals International, Inc.
    • ZeaVision LLC.
    • Vitreoretinal Technologies Inc. (Inactive)
    • Richter Gedeon Nyrt.
    • Molecular Design International, Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • Ferris State University
    • European Vision Institute Clinical Research Network
    • Eye Research Center, Farabi Eye Hospital
    • Soroka University Medical Center
    • Association for Innovation and Biomedical Research on Light and Image
    • Ajou University School of Medicine
    • Retina Macula Institute
    • Chengdu University of Traditional Chinese Medicine
    • King Khaled Eye Specialist Hospital
    • University of Catania

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4881CTIDB

GlobalData's clinical trial report, "Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018" provides an overview of Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Proliferative Diabetic Retinopathy (NPDR). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Latest Clinical Trials News on Non-Proliferative Diabetic Retinopathy (NPDR) 29
  • Mar 20, 2018: Aflibercept shows promising data for nonproliferative DR 29
  • Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial 29
  • Feb 09, 2018: Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy 29
  • Clinical Trial Profile Snapshots 31

Appendix 67

  • Abbreviations 67
  • Definitions 67
  • Research Methodology 68
  • Secondary Research 68
  • About GlobalData 69
  • Contact Us 69
  • Source 69

List of Tables

List of Tables

  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region, 2018* 7
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries, 2018* 12
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 13
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 14
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 15
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 18
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase, 2018* 20
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 21
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 22
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 23
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 24
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 25
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 26
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 27
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 28

List of Figures

List of Figures

  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 13
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 14
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 15
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
  • Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 18
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 20
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 21
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 22
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 23
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 24
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 25
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 26
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 27
  • Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 28
  • GlobalData Methodology 68
Back to Top